Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials

International Journal of Cardiology

Volumn 211, Issue , 2016, Pages 88-95

  Kongwatcharapong, J ^a   Dilokthornsakul, P ^b,c   Nathisuwan, S ^a   Phrommintikul, A ^d   Chaiyakunapruk, N ^c,e,f,g  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF COLORADO   (United States)

^c NARESUAN UNIVERSITY   (Thailand)

^d Faculty of Medicine Chiang Mai University   (Thailand)

^e MONASH UNIVERSITY MALAYSIA   (Malaysia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cardiovascular; Dipeptidyl peptidase 4 inhibitors; Heart failure; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; ALOGLIPTIN; CANAGLIFLOZIN; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; VOGLIBOSE; ADAMANTANE; DIPEPTIDE;

AGE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CINAHL; COCHRANE LIBRARY; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFECT; EMBASE; FOLLOW UP; HEART FAILURE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT OUTCOME;

ADAMANTANE; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84962810190     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.02.146     Document Type: Article

References (75)

1. N. Sarwar, P. Gao, S.R. Seshasai, R. Gobin, S. Kaptoge, E. Di Angelantonio, and et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet (London, England) 375 2010 2215 2222
2. N.J. Morrish, S.L. Wang, L.K. Stevens, J.H. Fuller, and H. Keen Mortality and causes of death in the WHO multinational study of vascular disease in diabetes Diabetologia 44 Suppl. 2 2001 S14 S21
3. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 356 2007 2457 2471
4. US DHHS F C Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes 2008
5. E.E. Mulvihill, and D.J. Drucker Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors Endocr. Rev. 35 2014 992 1019
6. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, and et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N. Engl. J. Med. 369 2013 1317 1326
7. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, and et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes N. Engl. J. Med. 369 2013 1327 1335
8. S. Wu, I. Hopper, M. Skiba, and H. Krum Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants Cardiovasc. Ther. 32 2014 147 158
9. M. Monami, I. Dicembrini, and E. Mannucci Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials Nutr. Metab. Cardiovasc. Dis. 24 2014 689 697
10. G. Savarese, P. Perrone-Filardi, C. D'Amore, C. Vitale, B. Trimarco, L. Pani, and et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis Int. J. Cardiol. 181 2015 239 244
11. J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, and et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N. Engl. J. Med. 373 2015 232 242
12. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, and et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17 1996 1 12
13. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, and et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials BMJ (Clinical research ed) 343 2011 d5928
14. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ (Clinical research ed) 339 2009 b2535
15. R. DerSimonian, and R. Kacker Random-effects model for meta-analysis of clinical trials: an update Contemporary clinical trials. 28 2007 105 114
16. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators Lancet (London, England) 355 2000 253 259
17. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat. Med. 21 2002 1539 1558
18. J.A. Sterne, A.J. Sutton, J.P. Ioannidis, N. Terrin, D.R. Jones, J. Lau, and et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials BMJ (Clinical research ed) 343 2011 d4002
19. C.B. Begg, and J.A. Berlin Publication bias and dissemination of clinical research J. Natl. Cancer Inst. 81 1989 107 115
20. M. Egger, and G.D. Smith Bias in location and selection of studies BMJ (Clinical research ed) 316 1998 61 66
21. R.E. Pratley, M.S. Kipnes, P.R. Fleck, C. Wilson, and Q. Mekki Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy Diabetes Obes. Metab. 11 2009 167 176
22. R.E. Pratley, J.E. Reusch, P.R. Fleck, C.A. Wilson, and Q. Mekki Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Curr. Med. Res. Opin. 25 2009 2361 2371
23. M.A. Nauck, G.C. Ellis, P.R. Fleck, C.A. Wilson, and Q. Mekki Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study Int. J. Clin. Pract. 63 2009 46 55
24. http://www.clinicaltrial.gov.
25. E. Bosi, G.C. Ellis, C.A. Wilson, and P.R. Fleck Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study Diabetes Obes. Metab. 13 2011 1088 1096
26. R.A. DeFronzo, C.F. Burant, P. Fleck, C. Wilson, Q. Mekki, and R.E. Pratley Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes J. Clin. Endocrinol. Metab. 97 2012 1615 1622
27. T. Haak, T. Meinicke, R. Jones, S. Weber, M. von Eynatten, and H.J. Woerle Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes. Metab. 14 2012 565 574
28. R. Kawamori, N. Inagaki, E. Araki, H. Watada, N. Hayashi, Y. Horie, and et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study Diabetes Obes. Metab. 14 2012 348 357
29. H. Yki-Jarvinen, J. Rosenstock, S. Duran-Garcia, S. Pinnetti, S. Bhattacharya, S. Thiemann, and et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a >/=52-week randomized, double-blind study Diabetes Care 36 2013 3875 3881
30. B. Gallwitz, J. Rosenstock, T. Rauch, S. Bhattacharya, S. Patel, M. von Eynatten, and et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Lancet (London, England) 380 2012 475 483
31. J. Rosenstock, C. Aguilar-Salinas, E. Klein, S. Nepal, J. List, and R. Chen Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes Curr. Med. Res. Opin. 25 2009 2401 2411
32. A. Pfutzner, E. Paz-Pacheco, E. Allen, R. Frederich, and R. Chen Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks Diabetes Obes. Metab. 13 2011 567 576
33. B. Goke, B. Gallwitz, J.G. Eriksson, A. Hellqvist, and I. Gause-Nilsson Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial Int. J. Clin. Pract. 67 2013 307 316
34. M. Nowicki, I. Rychlik, H. Haller, M.L. Warren, L. Suchower, and I. Gause-Nilsson Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment Diabetes Obes. Metab. 13 2011 523 532
35. P.L. Hollander, J. Li, R. Frederich, E. Allen, and R. Chen Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus Diab. Vasc. Dis. Res. 8 2011 125 135
36. R.A. DeFronzo, M.N. Hissa, A.J. Garber, J. Luiz Gross, R. Yuyan Duan, S. Ravichandran, and et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone Diabetes Care 32 2009 1649 1655
37. A.H. Barnett, B. Charbonnel, M. Donovan, D. Fleming, and R. Chen Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin Curr. Med. Res. Opin. 28 2012 513 523
38. T. Vilsboll, J. Rosenstock, H. Yki-Jarvinen, W.T. Cefalu, Y. Chen, E. Luo, and et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes Diabetes Obes. Metab. 12 2010 167 177
39. B. Charbonnel, A. Karasik, J. Liu, M. Wu, and G. Meininger Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 29 2006 2638 2643
40. J.C. Chan, R. Scott, J.C. Arjona Ferreira, D. Sheng, E. Gonzalez, M.J. Davies, and et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency Diabetes Obes. Metab. 10 2008 545 555
41. R.R. Henry, B. Staels, V.A. Fonseca, M.Z. Chou, R. Teng, G.T. Golm, and et al. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone - a factorial study Diabetes Obes. Metab. 16 2014 223 230
42. D. Williams-Herman, J. Johnson, R. Teng, G. Golm, K.D. Kaufman, B.J. Goldstein, and et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes Diabetes Obes. Metab. 12 2010 442 451
43. T.L. Seck, S.S. Engel, D.E. Williams-Herman, C.M. Sisk, G.T. Golm, H. Wang, and et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide Diabetes Res. Clin. Pract. 93 2011 e15 e17
44. K. Hermansen, M. Kipnes, E. Luo, D. Fanurik, H. Khatami, and P. Stein Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin Diabetes Obes. Metab. 9 2007 733 745
45. G. Schernthaner, J.L. Gross, J. Rosenstock, M. Guarisco, M. Fu, J. Yee, and et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 36 2013 2508 2515
46. F.J. Lavalle-Gonzalez, A. Januszewicz, J. Davidson, C. Tong, R. Qiu, W. Canovatchel, and et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 56 2013 2582 2592
47. J. Rosenstock, N. Aggarwal, D. Polidori, Y. Zhao, D. Arbit, K. Usiskin, and et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 35 2012 1232 1238
48. Y. Iwamoto, T. Taniguchi, K. Nonaka, T. Okamoto, K. Okuyama, J.C. Arjona Ferreira, and et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus Endocr. J. 57 2010 383 394
49. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res. = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2007;39:218-23.
50. E. Ferrannini, V. Fonseca, B. Zinman, D. Matthews, B. Ahren, S. Byiers, and et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy Diabetes, obesity & metabolism 11 2009 157 166
51. A.J. Garber, A. Schweizer, M.A. Baron, E. Rochotte, and S. Dejager Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study Diabetes Obes. Metab. 9 2007 166 174
52. J. Rosenstock, M.A. Baron, S. Dejager, D. Mills, and A. Schweizer Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial Diabetes Care 30 2007 217 223
53. W.D. Strain, V. Lukashevich, W. Kothny, M.J. Hoellinger, and P.M. Paldanius Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study Lancet (London, England) 382 2013 409 416
54. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm. Metab. Res. = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2009;41:905-9.
55. J. Rosenstock, J.E. Foley, M. Rendell, M. Landin-Olsson, J.J. Holst, C.F. Deacon, and et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance Diabetes Care 31 2008 30 35
56. https://www.novctrd.com/CtrdWeb/trialresults.nov.
57. I.M. Leck, and E.L. Millar Incidence of malformations since the introduction of thalidomide Br. Med. J. 2 1962 16 20
58. A. Pazin-Filho, A. Kottgen, A.G. Bertoni, S.D. Russell, E. Selvin, W.D. Rosamond, and et al. HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study Diabetologia 51 2008 2197 2204
59. H.C. Gerstein, K. Swedberg, J. Carlsson, J.J. McMurray, E.L. Michelson, B. Olofsson, and et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program Arch. Intern. Med. 168 2008 1699 1704
60. M. Lind, M. Olsson, A. Rosengren, A.M. Svensson, I. Bounias, and S. Gudbjornsdottir The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes Diabetologia 55 2012 2946 2953
61. S. Erqou, C.T. Lee, M. Suffoletto, J.B. Echouffo-Tcheugui, R.A. de Boer, J.P. van Melle, and et al. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis Eur. J. Heart Fail. 15 2013 185 193
62. W. Zhao, P.T. Katzmarzyk, R. Horswell, Y. Wang, J. Johnson, and G. Hu HbA1c and heart failure risk among diabetic patients J. Clin. Endocrinol. Metab. 99 2014 E263 E267
63. D.H. Solomon, S. Schneeweiss, R.J. Glynn, Y. Kiyota, R. Levin, H. Mogun, and et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults Circulation 109 2004 2068 2073
64. J.R. Ussher, and D.J. Drucker Cardiovascular actions of incretin-based therapies Circ. Res. 114 2014 1788 1803
65. E.K. Jackson Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome Hypertension 56 2010 581 583
66. C.F. Deacon Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review Diabetes Obes. Metab. 13 2011 7 18
67. R. Baetta, and A. Corsini Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences Drugs 71 2011 1441 1467
68. A. Ceriello, L. Sportiello, C. Rafaniello, and F. Rossi DPP-4 inhibitors: pharmacological differences and their clinical implications Expert Opin. Drug Saf. 13 Suppl. 1 2014 S57 S68
69. E.K. Jackson, J.H. Dubinion, and Z. Mi Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure Clin. Exp. Pharmacol. Physiol. 35 2008 29 34
70. D.J. Drucker Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action Diabetes Care 30 2007 1335 1343
71. E.K. Jackson, Z. Mi, S.P. Tofovic, and D.G. Gillespie Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent Hypertension 65 2015 238 249
72. S. Smooke, T.B. Horwich, and G.C. Fonarow Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure Am. Heart J. 149 2005 168 174
73. J.E. Ho, P. Gona, M.J. Pencina, J.V. Tu, P.C. Austin, Vasan RS, and et al. Discriminating clinical features of heart failure with preserved vs reduced ejection fraction in the community Eur. Heart J. 33 2012 1734 1741
74. A. Coats, and L. Shewan The Management of Heart Failure with Preserved Ejection Fraction (HFpEF) 2014 2014 1 5
75. J. Sanderson Comments on "The management of Heart Failure with preserved ejection fraction" 2015 2015 1